StudyRareStudyRare

Lysine catabolism

Log in to star
Amino acid metabolism

Last updated Nov 4, 2026

Log in to add personal notes on this page.

Lysine is broken down by two routes, the saccharopine pathway and the pipecolic acid pathway, which meet at alpha-aminoadipic semialdehyde. Its carbon skeleton then joins that of hydroxylysine and tryptophan at glutaryl-CoA before reaching the Krebs cycle. Two disorders sit on this pathway, one early and one late, and both act on the brain rather than causing the acidotic crises of the propionate pathway. Both are treated in part by limiting the lysine that enters the pathway.

the saccharopine and pipecolic acidpathwaysthey meet at alpha-aminoadipicsemialdehyde (alpha-AASA) and itscyclic form,piperideine-6-carboxylate (P6C),which are in equilibriumalpha-aminoadipic semialdehydedehydrogenase (antiquitin)ALDH7A1pyridoxine-dependent epilepsylysine, hydroxylysine, and tryptophanconverge on glutaryl-CoAglutaryl-CoA dehydrogenaseGCDH; mitochondriaglutaric aciduria type 1lysinealpha-AASA, inbalance with P6Calpha-aminoadipicacidglutaryl-CoAhydroxylysine,tryptophancrotonyl-CoA
Figure: lysine breakdown through alpha-aminoadipic acid to glutaryl-CoA, where hydroxylysine and tryptophan join it, with pyridoxine-dependent epilepsy and glutaric aciduria type 1 at the steps they block.
  1. lysine → alpha-aminoadipic semialdehyde (alpha-AASA): the saccharopine pathway. The pipecolic acid pathway makes the cyclic form of alpha-AASA, piperideine-6-carboxylate (P6C), and the two forms are in equilibrium, so both routes meet here.
  2. alpha-AASA → alpha-aminoadipic acid: alpha-aminoadipic semialdehyde dehydrogenase, also called antiquitin (ALDH7A1), an aldehyde dehydrogenase. Blocked in pyridoxine-dependent epilepsy.
  3. Lysine, hydroxylysine, and tryptophan converge on glutaryl-CoA.
  4. glutaryl-CoA → crotonyl-CoA: glutaryl-CoA dehydrogenase (GCDH), mitochondria. Blocked in glutaric aciduria type 1.
  • Pyridoxine-dependent epilepsy: alpha-AASA and P6C build up, and P6C condenses with pyridoxal 5'-phosphate, the active form of vitamin B6, and inactivates it. The result is neonatal or infantile seizures that resist anti-seizure medications and stop with large doses of pyridoxine, within minutes of an intravenous dose or within three to five days by mouth. Lysine restriction and L-arginine, which competes with lysine for transport, lower the load ("triple therapy" with pyridoxine). Neuronal migration abnormalities and a thin corpus callosum are not reversed by any of the three.
  • Glutaric aciduria type 1: glutaric acid, 3-hydroxyglutaric acid, glutarylcarnitine (C5DC), and glutaconic acid accumulate. Glutaric and 3-hydroxyglutaric acids are toxic to the striatum, so an illness-triggered crisis in infancy or early childhood can cause sudden, usually permanent dystonia. Macrocephaly with frontotemporal hypoplasia is common, and subdural hemorrhage can occur. Treatment is a low-lysine diet, carnitine, and avoiding catabolism; the risk of brain injury is highest in the first six years.
  • Urine and plasma alpha-AASA (with P6C, and with pipecolic acid, which builds up behind the block) mark pyridoxine-dependent epilepsy. Raised alpha-AASA is not specific: it also rises in molybdenum cofactor deficiency and isolated sulfite oxidase deficiency, told apart by urinary xanthine, hypoxanthine, and S-sulfocysteine in the first and high urinary sulfite in the second.
  • Glutarylcarnitine (C5DC) on the newborn screen and urine glutaric and 3-hydroxyglutaric acids mark glutaric aciduria type 1. Low excreters keep some enzyme activity and may show little in urine; screening finds about 84% of them, so a normal screen does not exclude it, and they carry a similar risk of striatal injury.
  • The clinical picture separates them before any lab returns: refractory neonatal seizures that stop with pyridoxine, against a macrocephalic infant who develops dystonia after a febrile illness.